Table 2. Treatment Outcomes.
| No Treatment(N = 43) | Open Placebo(N = 37) | p-value | |
| Midpoint (11 Days) | |||
| Global Improvement (IBS-GIS) | 4.0±1.1 | 5.2±1.0 | <.001 |
| Adequate Relief (IBS-AR) – no. (%) | 10 (23) | 18 (49) | .02 |
| Symptom Severity Reduction (IBS-SSS) | 28±66 | 75±87 | .008 |
| Quality of Life Improvement (IBS-QoL) | 4.4±8.9 | 8.3±11.6 | .10 |
| Endpoint (3 Weeks) | |||
| Global Improvement (IBS-GIS) | 3.9±1.3 | 5.0±1.5 | .002 |
| Adequate Relief (IBS-AR) – no. (%) | 15 (35) | 22 (59) | .03 |
| Symptom Severity Reduction (IBS-SSS) | 46±74 | 92±99 | .03 |
| Quality of Life Improvement (IBS-QoL) | 5.4±13.8 | 11.4±16.6 | .08 |
Note: All values are means ±SD except where noted. IBS = irritable bowel syndrome; IBS-GIS = IBS Global Improvement Scale; IBS-AR = IBS Adequate Relief; IBS-SSS = IBS Symptom Severity Scale; IBS-QoL = IBS Quality of Life Scale.